CRP and diastolic heart failure: Accordingly, we sought to determine the prevalence of elevated CRP in HFpEF and its association with clinical characteristics, PH and measures of HF severity in the well phenotyped cohort of HFpEF patients who participated in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart failure (RELAX) trial.